ES2135934T3 - Compuesto eventualmente bajo la forma de isomero optico puro o de mezcla de tales isomeros. - Google Patents

Compuesto eventualmente bajo la forma de isomero optico puro o de mezcla de tales isomeros.

Info

Publication number
ES2135934T3
ES2135934T3 ES96937390T ES96937390T ES2135934T3 ES 2135934 T3 ES2135934 T3 ES 2135934T3 ES 96937390 T ES96937390 T ES 96937390T ES 96937390 T ES96937390 T ES 96937390T ES 2135934 T3 ES2135934 T3 ES 2135934T3
Authority
ES
Spain
Prior art keywords
group
ilo
rent
fenile
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96937390T
Other languages
English (en)
Spanish (es)
Inventor
Samir Jegham
Alistair Lochead
Frederic Galli
Alain Nedelec
Axelle Solignac
Cruz Laurence De
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9513252A external-priority patent/FR2741069B1/fr
Priority claimed from FR9513253A external-priority patent/FR2741070B1/fr
Priority claimed from FR9602663A external-priority patent/FR2745574B1/fr
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Application granted granted Critical
Publication of ES2135934T3 publication Critical patent/ES2135934T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ES96937390T 1995-11-09 1996-11-05 Compuesto eventualmente bajo la forma de isomero optico puro o de mezcla de tales isomeros. Expired - Lifetime ES2135934T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9513252A FR2741069B1 (fr) 1995-11-09 1995-11-09 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR9513253A FR2741070B1 (fr) 1995-11-09 1995-11-09 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR9602663A FR2745574B1 (fr) 1996-03-04 1996-03-04 Derives de 5-phenyl-3-(piperidin-4-yl)-1, 3, 4-oxadiazol-2 (3h)-one, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
ES2135934T3 true ES2135934T3 (es) 1999-11-01

Family

ID=27253120

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96937390T Expired - Lifetime ES2135934T3 (es) 1995-11-09 1996-11-05 Compuesto eventualmente bajo la forma de isomero optico puro o de mezcla de tales isomeros.

Country Status (29)

Country Link
US (1) US5929089A (OSRAM)
EP (1) EP0863897B1 (OSRAM)
JP (1) JP4263240B2 (OSRAM)
CN (1) CN1077891C (OSRAM)
AR (1) AR004708A1 (OSRAM)
AT (1) ATE181328T1 (OSRAM)
AU (1) AU707325B2 (OSRAM)
BG (1) BG63463B1 (OSRAM)
BR (1) BR9611311A (OSRAM)
CA (1) CA2236357C (OSRAM)
CO (1) CO4770968A1 (OSRAM)
CZ (1) CZ287268B6 (OSRAM)
DE (1) DE69602970T2 (OSRAM)
EE (1) EE03487B1 (OSRAM)
ES (1) ES2135934T3 (OSRAM)
GR (1) GR3030823T3 (OSRAM)
HU (1) HUP0001168A3 (OSRAM)
IL (1) IL124364A (OSRAM)
MX (1) MX9803696A (OSRAM)
NO (1) NO309606B1 (OSRAM)
NZ (1) NZ321626A (OSRAM)
PL (1) PL186204B1 (OSRAM)
RU (1) RU2167160C2 (OSRAM)
SI (1) SI0863897T1 (OSRAM)
SK (1) SK282335B6 (OSRAM)
TR (1) TR199800827T2 (OSRAM)
TW (1) TW371303B (OSRAM)
UA (1) UA50748C2 (OSRAM)
WO (1) WO1997017345A1 (OSRAM)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW467902B (en) * 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
FR2762316B1 (fr) * 1997-04-18 1999-12-17 Sanofi Synthelabo Derives de 5-aryl-3-(8-azabicyclo[3.2.1] octan-3-yl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
EP0980370A1 (fr) * 1997-05-06 2000-02-23 Sanofi-Synthelabo Derives de 5-phenyl-1,3,4-oxadiazol-2(3h)-one et leur utilisation comme ligands 5-ht4
FR2763068B1 (fr) 1997-05-06 1999-06-04 Synthelabo Derives de 3-(pyrrolidin-3-yl)-1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
GB9715816D0 (en) * 1997-07-25 1997-10-01 Black James Foundation Histamine H receptor ligands
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
ATE310566T1 (de) 1998-09-18 2005-12-15 Alcon Mfg Ltd 5ht2-agoniste zur behandlung des glaukoms
CN1461216A (zh) * 1999-04-28 2003-12-10 呼吸器有限公司 用作治疗有关支气管收缩的机能障碍的药物的化合物
AU5861900A (en) * 1999-06-15 2001-01-02 Respiratorius Ab Receptor agonists and antagonists
WO2002012224A2 (en) * 2000-08-08 2002-02-14 Ortho Mcneil Pharmaceutical, Inc. Bicyclic compounds as h3 receptor ligands
WO2002012214A2 (en) * 2000-08-08 2002-02-14 Ortho Mcneil Pharmaceutical Inc. Non-imidazole aryloxyalkylamines as h3 receptor ligands
CA2419036A1 (en) 2000-08-08 2002-02-14 Ortho-Mcneil Pharmaceutical, Inc. Non-imidazole aryloxypiperidines as h3 receptor ligands
US7208497B2 (en) 2001-07-02 2007-04-24 Novo Nordisk A/S Substituted piperazines and diazepanes
WO2003004480A2 (en) 2001-07-02 2003-01-16 Novo Nordisk A/S Substituted piperazine and diazepanes as histamine h3 receptor agonists
EP1434765B1 (en) * 2001-09-14 2009-12-02 High Point Pharmaceuticals, LLC Substituted piperidines with selective binding to histamine h3-receptor
US20030186963A1 (en) 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
US6673829B2 (en) 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
JP4619655B2 (ja) 2001-09-14 2011-01-26 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 新規アミノアゼチジン、−ピロリジンおよび−ピペリジン誘導体
US7064135B2 (en) 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
EP1444219A1 (en) 2001-10-12 2004-08-11 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
US7005448B2 (en) 2001-12-14 2006-02-28 Alcon, Inc. Aminoalkyl-benzofuran-5-ol compounds for the treatment of glaucoma
US20030236259A1 (en) * 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
AU2005254800B2 (en) 2004-06-15 2010-12-09 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
BRPI0613564A2 (pt) 2005-07-04 2011-01-18 Novo Nordisk As compostos, seus usos na preparação de composições farmacêuticas e composições farmacêuticas compreendendo os mesmos
PL1959951T3 (pl) * 2005-12-01 2010-06-30 Hoffmann La Roche Heteroarylo-podstawione pochodne piperydyny jako inhibitory l-cpt1
AU2007267197B2 (en) * 2006-05-29 2011-12-01 High Point Pharmaceuticals, Llc 3- (1, 3-Benzodioxol-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine H3 receptor antagonist
EP2014656A3 (en) * 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
MX337721B (es) * 2011-09-19 2016-03-16 Suven Life Sciences Ltd Compuestos de heteroarilo como ligandos del receptor 5-ht4.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055476A (en) * 1990-08-13 1991-10-08 Hoechst-Roussel Pharmaceuticals Incorporated 3-(1,2-benzisoxazol-3-yl)-4-pyridinamines and derivatives
WO1993003725A1 (en) * 1991-08-20 1993-03-04 Smithkline Beecham Plc 5-ht4 receptor antagonists
DK0604494T3 (da) * 1991-09-12 1999-11-29 Smithkline Beecham Plc 5-HT4-receptorantagonister
AU667874B2 (en) * 1992-02-06 1996-04-18 Smithkline Beecham Plc Benzopyran, benzothiopyran and benzofuran derivatives as 5-HT4 antagonists
GB9219163D0 (en) * 1992-09-10 1992-10-28 Smithkline Beecham Plc Pharmaceuticals
JPH06157518A (ja) * 1992-11-27 1994-06-03 Yamanouchi Pharmaceut Co Ltd 新規なオキサジアゾール誘導体又はその塩

Also Published As

Publication number Publication date
DE69602970T2 (de) 2000-01-20
TW371303B (en) 1999-10-01
JP4263240B2 (ja) 2009-05-13
DE69602970D1 (de) 1999-07-22
PL186204B1 (pl) 2003-11-28
NO309606B1 (no) 2001-02-26
EE9800155A (et) 1998-12-15
EP0863897A1 (fr) 1998-09-16
AR004708A1 (es) 1999-03-10
CN1077891C (zh) 2002-01-16
SK59998A3 (en) 1998-11-04
CA2236357A1 (en) 1997-05-15
CN1202169A (zh) 1998-12-16
BG102412A (en) 1999-08-31
BR9611311A (pt) 1999-06-29
RU2167160C2 (ru) 2001-05-20
ATE181328T1 (de) 1999-07-15
JP2000500125A (ja) 2000-01-11
AU707325B2 (en) 1999-07-08
UA50748C2 (uk) 2002-11-15
CZ287268B6 (en) 2000-10-11
HK1016165A1 (en) 1999-10-29
NO982092L (no) 1998-06-29
IL124364A (en) 2001-08-08
AU7500196A (en) 1997-05-29
BG63463B1 (bg) 2002-02-28
HUP0001168A3 (en) 2001-07-30
CA2236357C (en) 2006-10-17
CZ142198A3 (cs) 1998-08-12
PL326671A1 (en) 1998-10-12
NO982092D0 (no) 1998-05-07
EE03487B1 (et) 2001-08-15
IL124364A0 (en) 1998-12-06
CO4770968A1 (es) 1999-04-30
WO1997017345A1 (fr) 1997-05-15
GR3030823T3 (en) 1999-11-30
EP0863897B1 (fr) 1999-06-16
HUP0001168A2 (hu) 2001-04-28
MX9803696A (es) 1998-09-30
SK282335B6 (sk) 2002-01-07
TR199800827T2 (xx) 1999-02-22
US5929089A (en) 1999-07-27
NZ321626A (en) 1998-10-28
SI0863897T1 (en) 1999-10-31

Similar Documents

Publication Publication Date Title
ES2135934T3 (es) Compuesto eventualmente bajo la forma de isomero optico puro o de mezcla de tales isomeros.
PA8538301A1 (es) Inhibidores de metaloproteinasas de matriz basados en pirimidinonas fusionadas
PA8491101A1 (es) Derivados de 4-fenil-piridin.
BR0208179A (pt) Composto, composição farmacêutica, métodos para tratar distúrbios associados com o receptor 5-ht6, distúrbios cognitivos, distúrbios da mémoria, psicose, esquizofrenia, e ansiedade, e, uso de um composto
AR035793A1 (es) Compuesto de ciclopropilindol, formulacion farmaceutica que lo comprende, su uso para preparar esta ultima y proceso para la preparacion de compuestos intermediarios para su sintesis
ES2135414T3 (es) Antagonistas del receptor 5-ht4.
FI75559C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 3-aminopropoxiarylderivat.
ATE106401T1 (de) Benzodiazepin-analoge.
NO20020823D0 (no) Heterosykliske forbindelser og deres anvendelse som metabotrofisk glutamatreseptor-antagonister
EA200100535A1 (ru) Цементирующая композиция и ее применение для цементирования нефтяных скважин или подобных сооружений
EA200101223A1 (ru) Новые соединения, их применение и получение
PE20040937A1 (es) Derivados de piridazin-3(2h)-ona como inhibidores de fosfodiesterasa-4 (pde 4)
DK1085896T3 (da) Somatostatinanaloger cykliseret med konformationelt begrænset skelet
PA8556301A1 (es) Compuestos pirimidina de anillo fusionado alquinilado
DK0626381T3 (da) Fremstilling af form 1 ranitidinhydrochlorid
BR0100234A (pt) Compostos de piperidina-4-sulfonamida, processo para a sua preparação e composições farmacêuticas contendo os mesmos
ES2152237T3 (es) Pirazolo(4,3-c)piridinas, un procedimiento para su preparacion y su uso como inhibidores de la recaptacion de serotonina.
ES2154605A1 (es) Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3
ES2089255T3 (es) N-(ariloxialquil)heteroaril-8-azabiciclo(3.2.1)octanos, compuestos intermedios y un procedimiento para su preparacion y su uso como medicamentos.
Hurevich et al. Novel method for the synthesis of urea backbone cyclic peptides using new Alloc‐protected glycine building units
EP0725068A4 (en) INDOLDER DERIVATIVES
DE69226119D1 (de) Cholecystokininantagoniste
Szermerski et al. Fluorinated GluN2B receptor antagonists with a 3‐Benzazepine scaffold designed for PET studies
ES2171306T3 (es) Compuesto bajo la forma de isomero geometrico puro o de una mezcla de estos isomeros.
ES2165410T3 (es) Nuevas 5-(ariloxi-metil)-oxazolinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.

Legal Events

Date Code Title Description
FC2A Grant refused

Effective date: 19981001

FG2A Definitive protection

Ref document number: 863897

Country of ref document: ES